

Peter J. D. Andrews
Giuseppe Citerio
Luca Longhi
Kees Polderman
Juan Sahuquillo
Peter Vajkoczy
Neuro-Intensive Care and
Emergency Medicine (NICEM)
Section of the European Society of
Intensive Care Medicine

NICEM consensus on neurological monitoring in acute neurological disease

Received: 3 March 2008
Accepted: 15 March 2008
Published online: 9 April 2008
© Springer-Verlag 2008

Endorsement The NICEM Academic and Industry Workshop held in Berlin, 2007, was endorsed by the European Society of Intensive Care Medicine and this guideline manuscript has been endorsed by the Editorial and Publishing Committee of the society.

Conflicts of interest P.J.D.A. is on the Speakers' Bureau of Integra Neuroscience. G.C. is on the Speakers' Bureau of Codman Italy for educational activities on neuromonitoring; he is the Principal Investigator of a European trial on Rehaumedic ICP device (sponsor BrainIT).

This manuscript summarises the Consensus on Neuromonitoring in Neuro-Intensive Care promoted and organised by the Neuro-Intensive Care and Emergency Medicine Section of the European Society of Intensive Care Medicine. The meeting was held during the 21st ESICM Annual Meeting in Berlin, 7 October 2007.

Electronic supplementary material

The online version of this article (doi:10.1007/s00134-008-1103-y) contains supplementary material, which is available to authorized users.

P. J. D. Andrews
University of Edinburgh & Lothian
University Hospitals Division, Department
of Anaesthetics, Critical Care & Pain
Medicine,
Edinburgh, Scotland

P. J. D. Andrews (✉)
Western General Hospital,
Crewe Road South, EH4 2XU
Edinburgh, UK
e-mail: p.andrews@ed.ac.uk

G. Citerio
San Gerardo Hospital, Neuroanesthesia and
Neurosurgical Intensive Care Unit,
Department of Perioperative Medicine and
Intensive Care,
Monza, Italy

L. Longhi
University of Milan, Neurosurgical
Intensive Care Unit, Department of
Anaesthesia and Critical Care Medicine,
Fondazione IRCCS Ospedale Maggiore
Policlinico, Mangiagalli e Regina Elena,
Milan, Italy

K. Polderman
Utrecht University Medical Center,
Department of Intensive Care,
Utrecht, The Netherlands

J. Sahuquillo
Vall d'Hebron University Hospital,
Universitat Autònoma de Barcelona,
Division of Neurosurgery,
Barcelona, Spain

P. Vajkoczy
Charité Universitätsmedizin Berlin,
Department of Neurosurgery,
Berlin, Germany

promoted and organised by the Neuro-Intensive Care and Emergency Medicine (NICEM) Section of the European Society of Intensive Care Medicine (ESICM). It is expected that continuous monitoring using multi-modal techniques will help to overcome the limitations of each individual method and will provide a better diagnosis. More specific treatment can then be applied; however, it remains to be determined which combination of parameters is optimal. The questions discussed and addressed in this manuscript are: (1) Who should have ICP monitoring and for how long? (2) What ICP technologies are available and what are their relative advantages/disadvantages? (3) Should CPP monitoring and autoregulation testing be used? (4) When should brain tissue oxygen tension (PbrO₂) be monitored? (5) Should structurally normal or abnormal tissue be monitored with PbrO₂? (6) Should microdialysis be considered in complex cases? It is hoped that this document will prove useful to clinicians working in NICU and also to those developing specialist NICU services within their hospital practice.

Abstract This manuscript summarises the consensus on neuro-monitoring in neuro-intensive care

Keywords Intracranial pressure monitoring · Cerebral perfusion pressure · Brain tissue oxygenation · Microdialysis

Introduction

The mission of the Neuro-Intensive Care and Emergency Medicine section of the European Society of Intensive Care Medicine (NICEM; <http://www.esicm.org>) is to improve outcomes for patients with life-threatening neurological illnesses. In particular, NICEM undertakes to promote and develop standards for training and physician competencies in the subspecialty of neurological intensive care.

NICEM has successfully run two post-graduate courses on neuro-intensive care, directed by P.J.D.A. and G.C., in 2005 and 2006. At the Barcelona congress in 2006 we used high-fidelity simulation as a teaching aid and following that session received many questions about neurological monitoring equipment. It became clear that there was an urgent need for some guidance on advanced neurological monitoring.

We organised, as a satellite to the 2007 Annual ESICM Congress, an academic workshop with the aim of producing a consensus on neurological monitors for the society.

The instructions to the discussants and speakers at the meeting, were to present only level 1 evidence and tertiary research, where this existed, and conclude with three to four bullet points for review by the expert panellists. The questions the experts were asked to address were:

1. Who should have ICP monitoring and for how long?
2. What ICP technologies are available and what are their relative advantages/disadvantages?
3. Should CPP monitoring and autoregulation testing be used?
4. When should brain tissue oxygen tension (P_{brO_2}) be monitored?
5. Should structurally normal or abnormal tissue be monitored with P_{brO_2} ?
6. Should microdialysis be considered in complex cases?

There are no studies, to our knowledge, that have shown benefit from any patient monitor. Thus, it appears that many studies support the need for specialist care but several factors, including the use of advanced neurological monitors, subspecialty-trained personnel and the development of evidence-based medicine patient care protocols, may explain the improvements in patient outcomes, making it difficult to distinguish between the effect of specialist personnel themselves, care pathways they initiate and the relative importance of the specialised monitors. There has, however, been a decrease in mortality and an improvement in outcome associated with the development of all these factors.

We will consider the specialised monitors in this monograph.

Who should have ICP monitoring and for how long?

The fundamental principles of raised intracranial pressure (ICP) are condensed in the doctrine credited to Monro (1783) and Kellie (1824). Briefly, this doctrine states that, once the fontanelles and sutures are closed, the brain is enclosed in a non-expandable case of bone, the brain parenchyma is nearly incompressible, the volume of the blood in the cranial cavity is therefore nearly constant and a continuous outflow of venous blood from the cranial cavity is required to make room for incoming arterial blood [1].

Raised ICP is an important "secondary insult" in brain-injured patients and a predictor of poor outcome after TBI [2]. ICP is also used to calculate cerebral perfusion pressure (CPP), which represents the pressure gradient across the cerebral vascular bed and is used as a therapeutic target for brain-injured patients in many intensive care units and is recommended by the Brain Trauma Foundation's (BTF) evidence-based guideline [3].

However, it is important to realise that there has never been a randomised controlled trial showing an outcome benefit for patients with ICP monitoring and ICP-guided treatment compared with patients without ICP monitoring. To date only prospective cohort trials and observational databases in patient groups at greatest risk of raised ICP have shown trends toward better outcomes when ICP is treated at a lower threshold [4]. These data are summarised in the BTF guidelines stating that ICP should be monitored in all salvageable patients with a severe traumatic brain injury (TBI) and an abnormal computed tomography (CT) scan [5].

Patients at risk of neurological deterioration or those who have severe acute brain injury are best cared for in specialist centres where there is a concentration of expertise to address acute brain injury and its complications. Separating the impact of the availability of these specialists on patient outcome from the effect of ICP monitoring and ICP-guided treatments can be difficult [6].

The duration of monitoring will depend on normalisation of ICP and is highly dependent on individual patient characteristics. An option is to stop monitoring after 12–48 h with no pharmacological interventions and normalisation of $PaCO_2$.

In summary, ICP is a complex parameter which contains information about cerebral compensatory mechanisms and mechanisms contributing to cerebral blood flow (CBF) regulation. ICP control requires continuous ICP monitoring and integration of the additional information in the ICP waveforms [7] and their relationship to MAP to help us understand the underlying pathophysiology.

Consensus statement:

- We recommend that all patients with severe TBI should be managed in specialised centres.
- There are insufficient data to recommend ICP monitoring and management as standard care in all brain-injury patients. Nevertheless, the evidence is “good enough” to recommend ICP monitoring of patients with severe injuries who are at increased risk of intracranial hypertension.
- Which patients are at “high risk” of ICP elevation is a matter of controversy. We recommend ICP should be monitored in all salvageable patients with a severe TBI (i.e. Glasgow Coma Scale Score \leq 8) and an abnormal CT scan.
- We recommend that the management of raised ICP should follow BTF guidelines with care to exclude surgical lesions, including haematoma, contusion and hydrocephalus. Local protocols should be developed that conform to international guidelines and include neurosurgical consultation.

What ICP technologies are available and what are their relative advantages/disadvantages?

The optimal ICP monitoring device should be accurate, reliable, cost effective, and cause minimal patient morbidity, as stated by Lundberg [8]. Accuracy and reliability are defined according to the Association for the Advancement of Medical Instrumentation (AAMI) standards (<http://www.aami.org/standards/index.html>). An ICP device should have the following specifications: pressure range 0–100 mmHg, accuracy \pm 2 mmHg in the 0–20 mmHg range and maximum error of 10% in the 20–100 mmHg range, ANSI/AAMI NS28:1988/(R)2006 – Intracranial pressure monitoring devices (ANSI: American National Standards Institute).

Ventricular fluid pressure is the established reference standard for measuring ICP. Currently, the ventricular catheter (VC) connected to an external strain gauge transducer is the most accurate, low-cost, and reliable method of monitoring ICP [2]. This method has been proven to be reliable, permits periodic recalibration and allows therapeutic CSF drainage. Nevertheless, obstruction of the system and the requirement to consistently maintain the external transducer at a fixed reference point, usually the external auditory meatus, can lead to inaccuracy during clinical use [9]. The incidence of such problems has not been evaluated precisely. Furthermore, VC requires the implementation of quality control mechanisms, including accuracy and reliability. A major disadvantage is that its performance is dependent on human interaction (calibration, choice of reference level, etc.).

The potential risks of difficulty in placement, the need for frequent recalibration and the risk of obstruction

and infection have led to the development of alternative intracranial sites and technologies for ICP monitoring [2]. The most common alternative location for ICP monitoring is the cerebral parenchyma. Intraparenchymal transducers may be classified as solid-state, based on pressure-sensitive resistors, or fiberoptic design (FOD). Although both systems are very accurate at the time of placement, they have been reported to drift over time. Published research on this widely used technology (> 100,000 sensors sold worldwide in 2006) and especially independent comparative tests are scarce [10, 11]. No standard evaluation has been defined. For example, the use of correlation coefficient to compare these monitoring devices against the gold standard is inappropriate, and agreement should be evaluated using the method described by Bland and Altman [12]. Precision of parenchymal ICP monitors has been assessed by comparing the measurement value at the time of ICP monitor removal with atmospheric pressure [13]. Better information about the measurement inaccuracy and tolerance, i.e. the maximum expected error expressed as a percentage of a clinically relevant pressure range, is desirable, and data on this topic should be collected prospectively and independently in large series. The cost of these devices is higher than that of the cheaper ventricular system and FOD devices suffer from a higher intrinsic fragility.

Subdural and epidural monitors and externally placed anterior fontanelle monitors are less accurate than the above-mentioned devices. The overall safety of ICP monitoring devices is good, with clinically significant complications (e.g. infection and haematoma) occurring infrequently in centres with enough expertise [2]. Further improvement in ICP monitoring technology should focus on developing systems incorporating derived information, for example software for estimating autoregulation, and/or multi-parametric devices that could also monitor parameters such as PbrO_2 , temperature, CBF and other metabolic parameters in addition to ICP. Several techniques for non-invasive (indirect) assessment of ICP have been proposed over the years; at this stage none of them has reached sufficient maturity for clinical use.

Consensus statement:

- There is a need for standardisation and independent testing of ICP devices that verify the AAMI’s standards in real life. These tests should be conducted both in the laboratory and in the clinical environments. Larger studies than have so far been published are required.
- Despite the limitations described above, according to the BTF guidelines the VC should be considered as the “gold standard” for ICP monitoring. Errors may be more common in routine clinical practice than in laboratory tests, and the human factor should also be con-

sidered a potential source of error. Alternatively, intraparenchymal devices are an adequate choice for ICP monitoring.

- New multi-parametric devices and non-invasive systems are expected to reach the market in the near future. They require further validation and identification of clinical situations in which they could be used instead of invasive monitoring.

Should CPP monitoring and autoregulation testing be used?

The indications and thresholds for monitoring of CPP i.e. the difference between mean arterial pressure (MAP) and ICP, remain controversial. According to BTF guidelines, the general recommendation for target CPP values lies within the range of 50–70 mmHg [4]. CPP values below 50 mmHg carry a 2–3 times higher risk of cerebral ischaemia and cerebral hypo-perfusion, while CPP values beyond 70 mmHg may be associated with an increased incidence of systemic complications such as cardio-respiratory failure [14, 15].

Recently, it has become clear that these broad recommendations are non-physiological. In fact, the risk/benefit ratio of CPP-directed therapy aiming at CPP target value of 70 mmHg versus an ICP-directed therapy tolerating lower CPP values depends on the state of the individual's cerebrovascular autoregulation.

In the recent BTF guidelines, autoregulation has been mentioned for the first time and the caveat has been raised that in individual cases the traditional CPP limits may not be appropriate. Some evidence as to whether ICP-guided or CPP-guided therapy is better may depend on the state of autoregulation: if the autoregulation is intact a CPP-directed therapy could be used, with a higher probability of favourable outcome, whereas if autoregulation is absent ICP-guided therapy may yield better results [16].

Because of these findings, a continuous assessment of both static and dynamic cerebral autoregulation has become an interesting adjunct to current neuromonitoring strategies. Cerebrovascular autoregulation may be determined by various approaches. One of the two most used bedside techniques is the online correlation between ICP and MAP (pressure reactivity index, PRx) and between middle cerebral artery (MCA) blood flow velocities and MABP (Mx) [17, 18]. Both strategies provide immediate and dynamic information on autoregulation at the bedside.

Using these techniques cerebral autoregulation can be monitored continuously and the decision between ICP-directed and CPP-directed therapies could be based on the autoregulatory state. It is noteworthy that the autoregulatory state is not a static but rather a dynamic variable, suggesting that the individualised treatment strategy should be re-evaluated regularly over the time course of the acute phase following brain injury.

In the future, ICP and CPP may not be the sole target parameters for managing brain-injured patients. Additional parameters, such as cerebral perfusion, cerebral oxygenation and cerebral metabolism, are currently being evaluated for their ability to guide treatments in acute brain injury. For example, manipulation of individual CPP targets based on monitoring of cerebral oxygenation (PbrO₂) and/or cerebral blood flow (rCBF), has been used successfully to decrease episodes of brain hypoxia [19].

Consensus statement:

- In general, ICP and CPP target values should be ≤ 20 mmHg and ≥ 50 to ≤ 70 mmHg, respectively.
- CPP values > 70 mmHg should only be targeted if cerebrovascular autoregulation is intact.
- If cerebrovascular autoregulation is lost, ICP-directed therapeutic strategies should be considered.

When should PbrO₂ be monitored?

The goal of monitoring the injured brain is to enable the detection of harmful physiological events, collectively defined as “secondary insults”, before they can cause irreversible damage to the brain. The cause of secondary insults can be generalised, i.e. affecting the entire brain – for example, episodes of hypotension/decreased CPP, global hypoxaemia or increased ICP – or local, i.e. occurring only in the injured area of the brain. The latter category is more difficult to detect than the former. Whether or not secondary insults lead to permanent brain injury depends on the intensity and duration of the harmful physiological event and on the susceptibility of the brain [20].

In theory, the detection of tissue hypoxia is of even greater importance in the area of neurocritical care, because the brain and spinal cord have a poorer tolerance for ischaemia than most other tissues, and because hypoxia/ischaemia are central mechanisms underlying brain damage in various types of acute neurological injury, e.g. TBI, subarachnoid haemorrhage (SAH), stroke and global anoxia. The only currently available device uses a miniaturised Clark electrode to measure PO₂ and the device also measures temperature, so that the oxygen tension can be adjusted. The physiological idea behind cerebral oxygen monitoring is that the PbrO₂ value accurately represents the balance between oxygen delivery and oxygen consumption in brain cells, and that changes in PbrO₂ will therefore reflect pathophysiological alterations. These changes could then be used to guide treatments to prevent or mitigate hypoxic injury. In addition, PbrO₂ probes can also be used to directly measure brain temperature in injured and non-injured areas of the brain. There is mounting evidence suggesting that high brain temperatures can

Table 1 Summary of the evidence from clinical and in vitro studies assessing the usefulness of PbrO₂ in critically ill patients with brain injury

| | |
|--|---|
| Meta-analyses | None |
| Prospective randomised clinical trials with hard endpoints | None |
| Prospective clinical trials with outcome assessment | None |
| Observational clinical studies linking low PbrO ₂ to adverse outcome | Five small to medium-sized studies; total of 216 patients [24–28] |
| Clinical studies using PbrO ₂ to guide interventions using hard endpoints to compare efficacy | One study with historical controls providing outcome data [31] |
| Clinical studies using PbrO ₂ to guide interventions using secondary parameters to compare efficacy | One study [29] |
| Animal studies | Limited number of studies in cats and pigs [48–50] |

aggravate brain injury, and that brain temperature often exceeds core temperature measured at other sites [21]; thus, direct measurements of brain temperature could be helpful in treating brain-injured patients.

As is the case with many other monitoring tools, there is a lack of data from clinical studies in critically ill patients. The available evidence is summarised in Table 1.

PbrO₂ appears to correlate well with regional CBF [22], and PET scan studies have suggested that PbrO₂ correlates with changes in regional SjO₂ (jugular venous oxyhaemoglobin saturation) in brain-injured patients in the clinical setting [23]. This supports the physiological notions underlying the usage of PbrO₂ to monitor brain injury, but provides no direct evidence that this can be used to guide treatments and improve outcome.

The two major conditions in which PbrO₂ monitoring has been applied are TBI and SAH.

Use of PbrO₂ monitoring in TBI

Five observational studies have reported that low PbrO₂ values in patients with TBI predict adverse outcome [24–27]. The largest study was performed by van den Brink et al. [28], who reported higher mortality and worse neurological outcome in a series of 101 patients with an initial PbrO₂ < 10 mmHg for ≥ 30 min and in those with PbrO₂ < 15 mmHg lasting ≥ 4 h. In addition, both the level and duration of low PbrO₂ correlated with mortality.

Longhi et al. [29] observed multiple episodes of brain hypoxia in the days following severe TBI both in pericontusional tissue and in normal-appearing tissue. Moderate hypoxia was detected in over half of the patients, and severe hypoxic episodes in 23% in normal appearing tissue and 34% in peri-contusional areas, even when ICP and CPP were normal.

The question whether these measurements can be used to improve outcome has not been well studied. Toliás et al. [30] studied the effect of normobaric hyperoxia treatment (FiO₂ of 1.0 beginning within 6 h of admission) on a number of secondary parameters, including PbrO₂. The authors reported improvements in PbrO₂ as well as in

other secondary parameters (lactate/pyruvate ratio, brain glucose, glutamate, lactate levels etc.) in patients treated with a FiO₂ of 1.0 compared to baseline and compared to historical controls.

Only one study has specifically used PbrO₂ to guide treatment. Stiefel [31] enrolled 28 patients with severe TBI in a protocol combining “traditional” ICP and CPP targets (ICP < 20 mmHg, CPP > 60 mmHg) with PbrO₂ monitoring (target PbrO₂ > 25 mmHg). Outcomes were compared to 25 historical controls that had been monitored with ICP and CPP targets only. Mortality rates were lower (25% vs. 44%, *p* < 0.05) in the group with the combined monitoring. However, it should be noted that mortality in the control group was high by current standards and that no neurological outcome assessment was reported.

Use of PbrO₂ monitoring in SAH

SAH is a condition that carries a high risk for delayed focal ischaemia [32]. The causes are:

1. Vascular compression (by intraparenchymal haematoma or a retractor during surgery).
2. Thromboembolic complications during aneurysm coiling procedures.
3. Temporary/permanent vascular occlusion during surgical clipping.
4. Development of vasospasm.

PbrO₂ monitoring has been used in the following situations:

1. Intraoperative monitoring for diagnosis of vascular occlusion [33].
2. Monitoring of the compressed peri-haematoma tissue [34].
3. Diagnosis of vasospasm-associated delayed ischaemia and evaluation of the efficacy of treatment for this condition [35, 36].

Suggested thresholds for brain hypoxia are in the range of 10–20 mmHg [37]; however, more preclinical investiga-

tion needs to be performed to determine the threshold and duration of brain hypoxia associated with irreversible histological brain damage and to establish which is the best therapeutic strategy to increase PbrO₂.

Consensus statement:

PbrO₂ measurement has not been tested in a prospective randomised controlled trial, but there is a physiologically plausible basis to suggest that PbrO₂ is a useful monitoring tool in patients following TBI and SAH.

- PbrO₂ monitoring can detect changes in regional brain oxygenation that may be missed by global monitoring such as SjO₂/AjDO₂, and can provide data continuously over long periods.
- Low PbrO₂ is associated with raised ICP, low CBF (global/regional) and with adverse clinical outcomes.
- Large prospective clinical trials are necessary to better evaluate this device and associated interventions.
- Relevant issues associated with PbrO₂ monitoring are costs, fragility and invasiveness of the technology. Costs and risk to the patients need to be justified. Coagulation parameters (especially platelet number and function) should be normal before insertion of a monitoring probe.

Should structurally normal or abnormal tissue be monitored with PbrO₂?

PbrO₂ value is highly dependent on O₂ diffusion from vasculature to a small amount of tissue [38]. Therefore, it is a regional monitoring, whose values are highly dependent on the location of the probe. The target area for PbrO₂ monitoring is a subject of debate.

TBI (normal tissue)

Most centres have measured PbrO₂ in the right “normal appearing” frontal subcortical white matter [37]. The most relevant data derived from PbrO₂ measured in normal tissue are:

- During the acute phase following TBI, PbrO₂ might be pathologic, despite a normal ICP/ CPP, suggesting that PbrO₂ might become a novel target for resuscitation following TBI [39].
- There is an association between low PbrO₂ values and poor outcome [25, 40].
- PbrO₂-pressure reactivity might be used to assess cerebrovascular pressure reactivity and might help individualise CPP [41].

- In the presence of normal CPP, several episodes of regional brain hypoxia (not disclosed by parameters of global oxygenation) occur up to 5 days post-injury, suggesting that PbrO₂ is complementary to SjO₂/AjDO₂ (arterio-jugular venous oxygen content difference) when monitored in normal appearing tissue [29].
- Because there is an association between brain hypoxia and outcome, a strategy of detection and correction of brain hypoxia is advisable [19].

TBI (peri-contusional tissue)

In patients with focal lesions such as cerebral contusions/subdural haematomas there is a considerable amount of cerebral tissue at risk of ischaemia [42]. In the hypodense peri-contusional tissue, PbrO₂ is lower than measured in the normal appearing tissue, despite a greater CPP, and regional hypoxia lasts longer than in normal appearing tissue. Normalisation of low PbrO₂ around cerebral contusions occurs over a period of days [29]. This vulnerable tissue could be an appropriate target for focal invasive monitoring of brain oxygenation. However, more preclinical work is needed to test whether interventions aimed at correcting peri-contusional brain hypoxia are associated with histological and functional improvements in models of focal injury.

SAH

PbrO₂ has been used for early detection of cerebral ischaemia by placing probes in vulnerable areas of the brain, for example near the area of the aneurysm and in the area perfused by the artery where the aneurysm has been coiled or clipped.

Consensus statement:

The preferred location for PbrO₂ monitoring depends on what information is sought.

- *TBI*: The choice should be individualised for each patient.
 - The target should be the vulnerable and potentially salvageable tissue: peri-contusional tissue (not the core of the lesion) and tissue underneath a subdural haematoma.
 - Eloquent locations should be avoided (i.e. left temporal lobe, motor cortex etc.).
 - Where structurally normal tissue is monitored, PbrO₂ should be monitored in the sub-cortical white matter of the more injured hemisphere.

- *SAH*
 - The target should be the cortex within the expected distribution area of the parent artery of the aneurysm, which is at highest risk for developing vasospasm and delayed ischaemia.

Should microdialysis be considered in complex cases?

Although we do not have robust evidence as to when or how to use this technique, a consensus conference published in 2004 recommended that microdialysis (MD; see ESM) could be used in patients with TBI who require ICP monitoring [43]. Regarding catheter placement, this conference recommended placing a single catheter in the right frontal region in patients with diffuse injuries, and two catheters (one in normal tissue and one in the pericontusional tissue) in patients with focal injuries (brain contusions, non-evacuated haematomas etc.) [44]. Concerning the biochemical markers to monitor, it was stated that the lactate/pyruvate ratio was currently the best marker of the brain redox state and an early biomarker of secondary ischaemic injury glucose; glycerol and glutamate are additional markers of developing brain tissue hypoxia [45]. Regarding ischaemic damage, it is important to remember that ischaemic hypoxia is just one of the many types of hypoxia that can be detected in the injured brain [46].

The use of new high cut-off membranes may make the future of MD look bright, with the potential to study all the neuro-inflammatory cascades elicited by TBI [47]. High-resolution MD also opens potential avenues in translational research, allowing in the near future the solution to the puzzle of the pathophysiology of TBI and the development of potential therapeutic targets.

Another avenue that can be explored with MD is the profiling of new potentially neuroprotective drugs. Although the presence of the drug in the extracellular fluid does not guarantee a neuroprotective effect, if the drug does not cross the blood–brain barrier it would plausibly indicate an inability of this drug to target the brain. A better understanding of the true concentrations of any drug found in the brain tissue should be the first step in selecting good candidates for neuroprotection. The system cost varies depending on the number of channels meas-

ured, and consumables cost approximately 570 euros per patient.

Consensus statement:

- Despite the increased use of MD in the management of severe TBI, there is no class I evidence for its routine use at the bedside.
- Microdialysis is the only tool that allows continuous measurement of tissue chemistry in the brain extracellular space. This information, when adequately integrated into the clinical management of severe TBI, is potentially more useful than the analysis of any biomarker in the peripheral blood.
- There is an increasing body of evidence stressing the relevance of non-ischaemic forms of brain tissue hypoxia. MD is an essential tool for a better understanding of these forms.
- High-resolution MD using membranes with a high cut-off will enable the recovery of cytokines, interleukins and other inflammatory mediators, which may increase the usefulness of MD.
- MD is also an excellent tool in evaluating the ability of potentially neuroprotective drugs to cross the blood–brain barrier

Conclusion

It is hoped that continuous monitoring using multi-modal techniques will help to overcome the limitations of each individual method and will provide a better diagnosis. More specific treatment can then be applied; however, it remains to be determined which parameters are optimal. The use of these techniques requires highly trained personnel to avoid the potential of generating artefacts and possible misinterpretation. We strongly recommend that all patients with acute life-threatening illness be managed in specialist units.

Acknowledgements. We thank Giulia Abate, MD, for keeping minutes of the meeting. We thank the device companies (in alphabetical order: Codman, Johnson&Johnson, Integra Neuroscience, Rehaumedic, Vitamed Technologies) that financially supported the meeting. Companies' representatives were present only as auditors and did not participate in the consensus discussion or in the preparation or revision of this manuscript.

References

- Andrews PJ, Citerio G (2004) Intracranial pressure. 1. Historical overview and basic concepts. *Intensive Care Med* 30:1730–1733
- Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, Joint Section on Neurotrauma and Critical Care, AANS/CNS (2007) Guidelines for the management of severe traumatic brain injury. VII. Intracranial pressure monitoring technology. *J Neurotrauma* 24 Suppl 1:S45–S54
- Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, Joint Section on Neurotrauma and Critical Care, AANS/CNS (2007) Guidelines for the management of severe traumatic brain injury. VIII. Intracranial pressure thresholds. *J Neurotrauma* 24 Suppl 1:S55–S58
- Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, Joint Section on Neurotrauma and Critical Care, AANS/CNS (2007) Guidelines for the management of severe traumatic brain injury. IX. Cerebral perfusion thresholds. *J Neurotrauma* 24 Suppl 1:S59–S64
- Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, Joint Section on Neurotrauma and Critical Care, AANS/CNS (2007) Guidelines for the management of severe traumatic brain injury. VI. Indications for intracranial pressure monitoring. *J Neurotrauma* 24 Suppl 1:S37–S44
- Patel HC, Bouamra O, Woodford M, King AT, Yates DW, Lecky FE (2005) Trends in head injury outcome from 1989 to 2003 and the effect of neurosurgical care: an observational study. *Lancet* 366:1538–1544
- Czosnyka M, Hutchinson PJ, Balestreri M, Hiler M, Smielewski P, Pickard JD (2006) Monitoring and interpretation of intracranial pressure after head injury. *Acta Neurochir* 96:114–118
- Lundberg N (1960) Continuous recording and control of ventricular fluid pressure in neurosurgical practice. *Acta Psychiatr Scand* 36:1–193
- Citerio G, Andrews PJ (2004) Intracranial pressure. 2. Clinical applications and technology. *Intensive Care Med* 30:1882–1885
- Czosnyka M, Czosnyka Z, Pickard JD (1996) Laboratory testing of three intracranial pressure microtransducers: technical report. *Neurosurgery* 38:219–224
- Morgalla MH, Mettenleiter H, Bitzer M, Fretschner R, Grote EH (1999) ICP measurement control: laboratory test of 7 types of intracranial pressure transducers. *J Med Eng Technol* 23:144–151
- Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1:307–310
- Koskinen LO, Olivecrona M (2005) Clinical experience with the intraparenchymal intracranial pressure monitoring Codman MicroSensor system. *Neurosurgery* 56:693–698; discussion 693–698
- Robertson CS, Valadka AB, Hannay HJ, Contant CF, Gopinath SP, Cormio M, Uzura M, Grossman RG (1999) Prevention of secondary ischemic insults after severe head injury. *Critical Care Med* 27:2086–2095
- Contant CF, Valadka AB, Gopinath SP, Hannay HJ, Robertson CS (2001) Adult respiratory distress syndrome: a complication of induced hypertension after severe head injury. *J Neurosurg* 95:560–568
- Howells T, Elf K, Jones PA, Ronne-Engstrom E, Piper I, Nilsson P, Andrews P, Enblad P (2005) Pressure reactivity as a guide in the treatment of cerebral perfusion pressure in patients with brain trauma. *J Neurosurg* 102:311–317
- Czosnyka M, Smielewski P, Piechnik S, Steiner LA, Pickard JD (2001) Cerebral autoregulation following head injury. *J Neurosurg* 95:756–763
- Czosnyka M, Smielewski P, Piechnik S, Schmidt EA, Seeley H, al-Rawi P, Matta BF, Kirkpatrick PJ, Pickard JD (2000) Continuous assessment of cerebral autoregulation – clinical verification of the method in head injured patients. *Acta Neurochir* 76:483–484
- Meixensberger J, Jaeger M, Vath A, Dings J, Kunze E, Roosen K (2003) Brain tissue oxygen guided treatment supplementing ICP/ CPP therapy after traumatic brain injury. *J Neurol Neurosurg Psychiatry* 74:760–764
- Ghajar J (2000) Traumatic brain injury. *Lancet* 356:923–929
- Diringan MN, Reaven NL, Funk SE, Uman GC (2004) Elevated body temperature independently contributes to increased length of stay in neurologic intensive care unit patients. *Critical Care Med* 32:1489–1495
- Scheufler KM, Rohrborn HJ, Zentner J (2002) Does tissue oxygen-tension reliably reflect cerebral oxygen delivery and consumption? *Anesth Analg* 95:1042–1048, table of contents
- Gupta AK, Hutchinson PJ, Fryer T, Al-Rawi PG, Parry DA, Minhas PS, Kett-White R, Kirkpatrick PJ, Mathews JC, Downey S, Aigbirhio F, Clark J, Pickard JD, Menon DK (2002) Measurement of brain tissue oxygenation performed using positron emission tomography scanning to validate a novel monitoring method. *J Neurosurg* 96:263–268
- Bardt TF, Unterberg AW, Hartl R, Kiening KL, Schneider GH, Lanksch WR (1998) Monitoring of brain tissue PO₂ in traumatic brain injury: effect of cerebral hypoxia on outcome. *Acta Neurochir* 71:153–156
- Valadka AB, Gopinath SP, Contant CF, Uzura M, Robertson CS (1998) Relationship of brain tissue PO₂ to outcome after severe head injury. *Critical Care Med* 26:1576–1581
- Zauner A, Doppenberg EM, Woodward JJ, Choi SC, Young HF, Bullock R (1997) Continuous monitoring of cerebral substrate delivery and clearance: initial experience in 24 patients with severe acute brain injuries. *Neurosurgery* 41:1082–1091; discussion 1091–1083
- van Santbrink H, Maas AI, Avezaat CJ (1996) Continuous monitoring of partial pressure of brain tissue oxygen in patients with severe head injury. *Neurosurgery* 38:21–31
- van den Brink WA, van Santbrink H, Steyerberg EW, Avezaat CJ, Suazo JA, Hogesteeger C, Jansen WJ, Kloos LM, Vermeulen J, Maas AI (2000) Brain oxygen tension in severe head injury. *Neurosurgery* 46:868–876; discussion 876–868
- Longhi L, Pagan F, Valeriani V, Magnoni S, Zanier ER, Conte V, Branca V, Stocchetti N (2007) Monitoring brain tissue oxygen tension in brain-injured patients reveals hypoxic episodes in normal-appearing and in peri-focal tissue. *Intensive Care Med* 33:2136–2142
- Tolias CM, Reinert M, Seiler R, Gilman C, Scharf A, Bullock MR (2004) Normobaric hyperoxia-induced improvement in cerebral metabolism and reduction in intracranial pressure in patients with severe head injury: a prospective historical cohort-matched study. *J Neurosurg* 101:435–444
- Stiefel MF, Spiotta A, Gracias VH, Garuffe AM, Guillaumondegui O, Maloney-Wilensky E, Bloom S, Grady MS, LeRoux PD (2005) Reduced mortality rate in patients with severe traumatic brain injury treated with brain tissue oxygen monitoring. *J Neurosurg* 103:805–811

32. Fergusen S, Macdonald RL (2007) Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. *Neurosurgery* 60:658–667; discussion 667
33. Kett-White R, Hutchinson PJ, Al-Rawi PG, Czosnyka M, Gupta AK, Pickard JD, Kirkpatrick PJ (2002) Cerebral oxygen and microdialysis monitoring during aneurysm surgery: effects of blood pressure, cerebrospinal fluid drainage, and temporary clipping on infarction. *J Neurosurg* 96:1013–1019
34. Stocchetti N, Chieregato A, De Marchi M, Croci M, Benti R, Grimaldi N (1998) High cerebral perfusion pressure improves low values of local brain tissue O₂ tension (PtiO₂) in focal lesions. *Acta Neurochir* 71:162–165
35. Hoelper BM, Hofmann E, Sporleder R, Soldner F, Behr R (2003) Transluminal balloon angioplasty improves brain tissue oxygenation and metabolism in severe vasospasm after aneurysmal subarachnoid hemorrhage: case report. *Neurosurgery* 52:970–974; discussion 974–976
36. Kett-White R, Hutchinson PJ, Al-Rawi PG, Gupta AK, Pickard JD, Kirkpatrick PJ (2002) Adverse cerebral events detected after subarachnoid hemorrhage using brain oxygen and microdialysis probes. *Neurosurgery* 50:1213–1221; discussion 1221–1212
37. Nortje J, Gupta AK (2006) The role of tissue oxygen monitoring in patients with acute brain injury. *Br J Anaesth* 97:95–106
38. Menon DK, Coles JP, Gupta AK, Fryer TD, Smielewski P, Chatfield DA, Aigbirhio F, Skepper JN, Minhas PS, Hutchinson PJ, Carpenter TA, Clark JC, Pickard JD (2004) Diffusion limited oxygen delivery following head injury. *Critical Care Med* 32:1384–1390
39. Stiefel MF, Udoetuk JD, Spiotta AM, Gracias VH, Goldberg A, Maloney-Wilensky E, Bloom S, Le Roux PD (2006) Conventional neurocritical care and cerebral oxygenation after traumatic brain injury. *J Neurosurg* 105:568–575
40. van den Brink WA, van Santbrink H, Avezaat CJ, Hogesteeger C, Jansen W, Kloos LM, Vermeulen J, Mass AI (1998) Monitoring brain oxygen tension in severe head injury: the Rotterdam experience. *Acta Neurochir* 71:190–194
41. Jaeger M, Schuhmann MU, Soehle M, Meixensberger J (2006) Continuous assessment of cerebrovascular autoregulation after traumatic brain injury using brain tissue oxygen pressure reactivity. *Critical Care Med* 34:1783–1788
42. Coles JP, Fryer TD, Smielewski P, Chatfield DA, Steiner LA, Johnston AJ, Downey SP, Williams GB, Aigbirhio F, Hutchinson PJ, Rice K, Carpenter TA, Clark JC, Pickard JD, Menon DK (2004) Incidence and mechanisms of cerebral ischemia in early clinical head injury. *J Cereb Blood Flow Metab* 24:202–211
43. Hutchinson PJ, O'Connell MT, Al-Rawi PG, Maskell LB, Kett-White R, Gupta AK, Richards HK, Hutchinson DB, Kirkpatrick PJ, Pickard JD (2000) Clinical cerebral microdialysis: a methodological study. *J Neurosurg* 93:37–43
44. Chaurasia CS, Muller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, Bungay PM, DeLange EC, Derendorf H, Elmquist WF, Hammarlund-Udenaes M, Joukhadar C, Kellogg DL Jr., Lunte CE, Nordstrom CH, Rollem H, Sawchuk RJ, Cheung BW, Shah VP, Stahle L, Ungerstedt U, Welty DF, Yeo H (2007) AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. *J Clin Pharmacol* 47:589–603
45. Bellander BM, Cantais E, Enblad P, Hutchinson P, Nordstrom CH, Robertsson C, Sahuquillo J, Smith M, Stocchetti N, Ungerstedt U, Unterberg A, Olsen NV (2004) Consensus meeting on microdialysis in neurointensive care. *Intensive Care Med* 30:2166–2169
46. Siggaard-Andersen O, Ulrich A, Gothen IH (1995) Classes of tissue hypoxia. *Acta Anaesthesiol Scand* 107:137–142
47. Hutchinson PJ, O'Connell MT, Rothwell NJ, Hopkins SJ, Nortje J, Carpenter KL, Timofeev I, Al-Rawi PG, Menon DK, Pickard JD (2007) Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-1beta, and their endogenous inhibitor IL-1ra. *J Neurotrauma* 24:1545–1557
48. Maas AI, Fleckenstein W, de Jong DA, van Santbrink H (1993) Monitoring cerebral oxygenation: experimental studies and preliminary clinical results of continuous monitoring of cerebrospinal fluid and brain tissue oxygen tension. *Acta Neurochir* 59:50–57
49. van Hulst RA, Hasan D, Lachmann B (2002) Intracranial pressure, brain PCO₂, PO₂, and pH during hypo- and hyperventilation at constant mean airway pressure in pigs. *Intensive Care Med* 28:68–73
50. Zauner A, Bullock R, Di X, Young HF (1995) Brain oxygen, CO₂, pH, and temperature monitoring: evaluation in the feline brain. *Neurosurgery* 37:1168–1176; discussion 1176–1167